Lexicon Pharmaceuticals Inc

NASDAQ:LXRX

1.58

+0.04 (+2.60%)

6:34:30 PM EDT: $1.62 +0.04 (+2.49%)

Market Cap (Intraday)	399.17M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.37 Million
Adjusted EPS	-$0.20

See more estimates

10-Day MA	$1.68
50-Day MA	$2.23
200-Day MA	$1.69

See more pivots

Lexicon Pharmaceuticals Inc Stock, NASDAQ:LXRX

2445 Technology Forest Boulevard, 11th floor, The Woodlands, Texas 77381-1160

United States of America

Phone: +1.281.863.3000

Number of Employees: 285

http://www.lexpharma.com

Description

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.